Marginal Zone Lymphoma
The latest news, research, and perspectives in marginal zone lymphoma (MZL).
Advertisement
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
Clinical evaluations of this bispecific antibody as monotherapy or in polytherapy for B-cell non-Hodgkin lymphomas continue.
This new approval adds upon the agent's indications for relapsed or refractory DLBCL and other large B-cell lymphomas.
Approved for adults ineligible for autologous transplant or CAR T-cell therapy following at least two systemic therapies.
In the TRANSCEND FL trial liso-cel has met primary and secondary endpoints for both MZL and FL with manageable safety.
Advertisement
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
The 5-year follow-up analysis of ZUMA-5 showed continued efficacy and no new safety signals.
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
The functional and structural relevance of IGHV1-204 remains unclear for patients with splenic marginal zone lymphoma.
Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.
A large, multicenter retrospective study found favorable efficacy and toxicity with this approach.
A phase I/II first-in-human study evaluates a new bivalent small molecule in relapsed or refractory FL and MZL.
Axi-cel showed promising efficacy and safety in patients with relapsed or refractory indolent non-Hodgkin lymphomas.
Two surrogate markers predicted treatment effect on eight-year progression-free survival in patients with extranodal MZL.
Dr. Nastoupil spoke about how the meeting can help clinicians learn how apply knowledge from the latest research.
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.